Occam Recruits CEO for Weight Loss Biotech Prolynx
In December 2025, Occam Global, a leading executive recruiting firm specializing in the life sciences, recruited obesity and commercial veteran Chris Boulton as CEO of Prolynx.
Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced the closing of a $70 million Series A financing co-led by 5AM Ventures and OrbiMed, along with Monograph Capital.
Boulton joins Prolynx after leading commercial planning for Amgen’s obesity portfolio, which includes the closely watched mid-stage prospect MariTide. Prior to that, he served as general manager of Sanofi's US diabetes portfolio.
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.